The role of the renin-angiotensin system in the appearance and progression of renal cell carcinoma: a literature review

Renal cell carcinoma (RCC) is one of the most common forms of malignant epithelial tumors of this localization. The development of new approaches to the diagnosis, prognosis and treatment of RCC is an topical issue of molecular medicine. The renin-angiotensin system (RAS) is not only an important component of the central and humoral mechanisms of controlling blood pressure and hydroelectrolytic balance, but also refers to the body systems involved in complex carcinogenesis pathways. Researches on the role of RAS in tumor progression are currently the priority. The data on the role of RAS in the development and progression of malignant tumors in the kidneys are being discussed. In this article, we present an overview of data on the role of RAS in the emergence and development of RCC, an analysis of the molecular mechanisms of development and progression of RCC, the prospects for using indicators of the RAS: angiotensin-converting enzymes (ACE), ACE2 and angiotensin II receptors as markers of diagnosis and monitoring of neoplastic transformation processes in the kidney. The prospects for the use of new, effective anticancer drugs with a targeted effect on definite indicators of the RAS of RCC were analyzed.

1. Malignant tumors in Russia in 2017 (morbidity and mortality). Eds.: А.D. Kaprin, V.V. Starinskiy, G.V. Petrova. Moscow: MNIOI im. P.A. Gertsena – filial FGBU “NMIRTS radiologii” Minzdrava Rossii, 2018. 250 p.(In Russ.).

2. Bray F., Ferlay J., Soerjomataram I. et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018;0:1–31. DOI: 10.3322/caac.21492.

3. Wong M.C.S., Goggins W.B., Yip B.H.K. et al. Incidence and mortality of kidney cancer: temporal patterns and global trends in 39 countries. Sci Rep 2017;7(1):15698. DOI: 10.1038/s41598017-15922-4.

4. Moch H., Cubilla A.L., Humphrey P.A. et al. The 2016 WHO classification of tumours of the urinary system and male genital organs. Part A: Renal, Penile, and Testicular Tumours. Eur Urol 2016;70(1):93–105. DOI: 10.1016/j.eururo.2016.02.029.

5. Brodaczewska K.K., Szczylik C., Fiedorowicz M. et al. Choosing the right cell line for renal cell cancer research. Mol Cancer 2016;15(1):83. DOI: 10.1186/s12943-0160565-8.

6. Rydzanicz M., Wrzesinski T., Bluyssen H.A., Wesoly J. Genomics and epigenomics of clear cell renal cell carcinoma: recent developments and potential applications. Cancer Lett 2013;341(2):111–26. DOI: 10.1016/j.canlet.2013.08.006.

7. Ager E.I., Neo J., Christophi C. The reninangiotensin system and malignancy. Carcinogenesis 2008;29(9):1675–84. DOI: 10.1093/carcin/bgn171.

8. George A.J., Thomas W.G., Hannan R.D. The renin-angiotensin system and cancer: old dog, new tricks. Nat Rev Cancer 2010;10(11):745–59. DOI: 10.1038/nrc2945.

9. Miyajima A., Kosaka T., Kikuchi E., Oya M. Renin-angiotensin system blockade: its contribution and controversy. Int J Urol 2015;22(8):721–30. DOI: 10.1111/iju.12827.

10. Wegman-Ostrosky T., Soto-Reyes E., VidalMillán S., Sánchez-Corona J. The reninangiotensin system meets the hallmarks of cancer. J Renin Angiotensin Aldosterone Syst 2015;16(2):227–33. DOI: 10.1177/1470320313496858.

11. Kogan M.I., Chernogubova E.A., Chibichyan M.B. et al. The role of kallikrein-kinin and angiotensin systems in the pathogenesis of prostate cancer. Urologiya = Urology 2015;(3):50–4. (In Russ.).

12. Kugaevskaya E.V., Timoshenko O.S., Solovyova N.I. Angiotensinconverting enzyme: antigenic properties of domains, the role of beta amyloid beta peptide in metabolism and tumor progression. Biomeditsinskaya khimiya = Biomedical Chemistry 2015;61(3):301–11. (In Russ.).

13. Carbajo-Lozoya J., Lutz S., Feng Y. et al. Angiotensin II modulates VEGF-driven angiogenesis by opposing effects of type 1 and type 2 receptor stimulation in the microvascular endothelium. Cell Signal 2012;24(6):1261–9. DOI: 10.1016/j.cellsig. 2012.02.005.

14. Wolgien M.D.C.G.M., Correa S.A.A., Breuel P.A.F. et al. Renin angiotensin system components and cancer: reports of association. J Biosci Med 2016;4:65–75.

15. Kim J.J., Huang P., Eisenberger M.A. et al. The role of angiotensin system inhibitors (ASIs) in the outcome of sunitinib treatment (tx) in patients (pts) with metastatic renal cell carcinoma (mRCC). J Clin Oncol 2011;29(15_suppl):e15008. DOI: 10.1200/jco.2011.29.15_suppl.e15008.

16. Derosa L., Izzedine H., Albiges L., Escudier B. Hypertension and angiotensin system inhibitors in patients with metastatic renal cell carcinoma. Oncol Rev 2016;10(2):298. DOI: 10.4081/oncol.2016.298.

17. Pasechnik D.G., Kogan M.I., Akhokhov Z.M. et al. Single nucleotide polymorphisms of genes related to the renin-angiotensin system in patients with renal cell cancer. Meditsinskiy vestnik Bashkortostana = Bashkortostan Medical Journal 2015;10(3):181–4. (In Russ.)

18. Eliseeva Yu.E. Angiotensin-converting enzyme, its physiological role. Voprosy meditsinskoy khimii = Questions of Medical Chemistry 2001;1:43–54. (In Russ.).

19. Peach M.J. Renin-angiotensin system: biochemistry and mechanisms of action. Physiol Rev 1977;57(2):313–70. DOI: 10.1152/physrev.1977.57.2.313.

20. Paul M., Mehr A.P., Kreutz R. Physiology of local renin-angiotensin systems. Physiol Rev 2006;86(3):747–803. DOI: 10.1152/physrev.00036.2005.

21. Brown M.J. Renin: friend or foe? Heart 2007;93:1026–33.

22. Yin G., Yan C., Berk B.C. Angiotensin II signaling pathways mediated by tyrosine kinases. Int J Biochem Cell Biol 2003;35(6):780–3. DOI: 10.1016/s13572725(02)00300-x.

23. Tipnis S.R., Hooper N.M., Hyde R. et al. A human homolog of angiotensin-converting enzyme. Cloning and functional expression as a captopril-insensitive carboxypeptidase. J Biol Chem.2000;275(43):33238–43. DOI: 10.1074/jbc.M002615200.

24. Donoghue M., Hsieh F., Baronas E. et al. A novel angiotensin-converting enzymerelated carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9. Circ Res 2000;87(5):E1–9. DOI: 10.1161/01.res.87.5.e1.

25. Santos R.A., Simoese Silva A.C., Maric C. et al. Angiotensin-(1–7) is an endogenous ligand for the G protein-coupled receptor Mas. Proc Natl Acad Sci USA 2003;100 (14):8258–63. DOI: 10.1073/pnas.1432869100.

26. Lv L.L., Liu B.C. Role of non-classical reninangiotensin system axis in renal fibrosis. Front Physiol 2015;6:117. DOI: 10.3389/fphys.2015.00117.

27. Zhuo J.L., Li X.C. New insights and perspectives on intrarenal renin-angiotensin system: focus on intracrine/intracellular angiotensin II. Peptides 2011;32(7): 1551–65. DOI: 10.1016/j.peptides.2011.05.012.

28. Sparks M.A., Crowley S.D., Gurley S.B. et al. Classical renin-angiotensin system in kidney physiology. Compr Physiol 2014;4(3):1201–28. DOI: 10.1002/cphy.c130040.

29. Gonzalez-Villalobos R.A., Shen X.Z., Bernstein E.A. et al. Rediscovering ACE: Novel insights into the many roles of the angiotensin-converting enzyme. J Mol Med (Berl) 2013;91(10):1143–54. DOI: 10.1007/s00109-013-1051-z.

30. Soler M.J., Wysocki J., Batlle D. ACE2 alterations in kidney disease. Nephrol Dial Transplant 2013;28(11):2687–97. DOI: 10.1093/ndt/gft320.

31. Mizuiri S., Hemmi H., Arita M. et al. Increased ACE and decreased ACE2 expression in kidneys from patients with IgA nephropathy. Nephron Clin Pract 2011;117(1):c57– 66. DOI: 10.1159/000319648.

32. Chappell M.C. Emerging evidence for a functional angiotensin-converting enzyme 2-angiotensin-(1-7)-MAS receptor axis: more than regulation of blood pressure? Hypertension 2007;50(4):596–9.

33. DOI: 10.1161/HYPERTENSIONAHA.106.076216.

34. Takada Y., Hiwada K., Yokoyama M. et al. Angiotensin converting enzyme. A possible histologic indicator for human renal cell carcinoma. Cancer 1985;56(1):130–3. DOI:10.1002/10970142(19850701)56:1<130::AIDCNCR2820560120>3.0.CO;2-Y.

35. Larrinaga G., Pérez I., Sanz B. et al. Angiotensinconverting enzymes (ACE and ACE2) are downregulated in renal tumors. Regul Pept 2010;165(2–3):218–23. DOI: 10.1016/j.regpep.2010.07.170.

36. Usmani B.A., Janeczko M., Shen R. et al. Analysis of the insertion/deletion polymorphism of the human angiotensin converting enzyme (ACE) gene in patients with renal cancer. Br J Cancer 2000;82(3):550–2. DOI: 10.1054/bjoc.1999.0962.

37. De Martino M., Klatte T., Schatzl G. et al. Insertion/deletion polymorphism of angiotensin I-converting enzyme gene is linked with chromophobe renal cell carcinoma. Urology 2011;77(4):1005.e9–13. DOI: 10.1016/j.urology.2010.11.033.

38. van der Knaap R., Siemes C., Coebergh J.W. et al. Renin-angiotensin system inhibitors, angiotensin I-converting enzyme gene insertion/ deletion polymorphism and cancer: The Rotterdam Study. Cancer 2008;112(4):748–57. DOI: 10.1002/cncr.23215.

39. Deckers I.A., van den Brandt P.A., van Engeland M. et al. Polymorphisms in genes of the renin-angiotensin-aldosterone system and renal cell cancer risk: interplay with hypertension and intakes of sodium, potassium and uid. Int J Cancer 2015;136(5):1104–16. DOI: 10.1002/ijc.29060.

40. Andreotti G., Boffetta P., Rosenberg P.S. et al. Variants in blood pressure genes and the risk of renal cell carcinoma. Carcinogenesis 2010;31(4):614–20. DOI: 10.1093/carcin/bgp321.

41. Zheng S., Yang Y., Song R. et al. Ang-(1-7) promotes the migration and invasion of human renal cell carcinoma cells via Masmediated AKT signaling pathway. J Biochem Biophys Res Commun 2015;460(2):333–40. DOI: 10.1016/j.bbrc.2015.03.035.

42. Norwood V.F., Craig M.R., Harris J.M., Gomez R.A. Differential expression of angiotensin II receptors during early renal morphogenesis. Am J Physiol 1997;272(2 Pt 2):R662–8. DOI: 10.1152/ajpregu.1997.272.2.R662.

43. Arendshorst W.J., Brännström K., Ruan X. Actions of angiotensin II on the renal microvasculature. J Am Soc Nephrol 1999;10(Suppl 11):S149–61.

44. Matsubara H., Sugaya T., Murasawa S. et al. Tissue-specific expression of human angiotensin II AT1 and AT2 receptors and cellular localization of subtype mRNAs in adult human renal cortex using in situ hybridization. Nephron 1998;80(1):25–34. DOI: 10.1159/000045121.

45. Goldfarb D.A., Diz D.I., Tubbs R.R. et al. Angiotensin II receptor subtypes in the human renal cortex and renal cell carcinoma. J Urol 1994;151(1):208–13. DOI: 10.1016/s0022-5347(17)34918-2.

46. Chatterjee P.K., Weerackody R.P., Mistry S.K. et al. Selective antagonism of the AT1 receptor inhibits angiotensin II stimulated DNA and protein synthesis in primary cultures of human proximal tubular cells. Kidney Int 1997;52(3): 699–705. DOI: 10.1038/ki.1997.385.

47. Cao Z., Kelly D.J., Cox A. et al. Angiotensin type 2 receptor is expressed in the adult rat kidney and promotes cellular proliferation and apoptosis. Kidney Int 2000;58(6):2437–51. DOI: 10.1046/j.1523-1755.2000.00427.x.

48. Martin B. et al. Angiotensin-2 receptors (AT1-R and AT2-R), new prognostic factors for renal clear-cell carcinoma? Br J Cancer 2010;103(11):1698–705. DOI: 10.1038/sj.bjc.6605866.

49. Dolley-Hitze T., Jouan F., Martin B. et al. Angiotensin-2 receptors (AT1-R and AT2-R), new prognostic factors for renal clear-cell carcinoma? Br J Cancer 2010;103(11):1698–705. DOI: 10.1038/sj.bjc.6605866.